To evaluate the safety and outcomes of continuing rapid infusion protocols pre- and post- switching from originator to biosimilar infliximab
Latest Information Update: 20 Nov 2019
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 20 Nov 2019 New trial record